Retatrutide is an investigational, once-weekly injectable triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly for treating obesity, type 2 diabetes, and metabolic diseases. Phase 2/3 trials show it produces significant weight loss (up to ~24-28% in 48 weeks) and improved metabolic markers by reducing appetite, increasing energy expenditure, and slowing gastric emptying
Product Care:
Store in a cool, dry place away from light. If Constituted, Please Refrigerate. For longer term storage, freezing at -20°C is recommended to maintain integrity.
Product Note:
All products are shipped in lyophilized or powder form and must be reconstituted to a liquid for research and testing. We are unable to provide any dosing instructions. All peptides are for research use only. We’re an expert biotechnology company that provides high quality peptides and products for purchase to advance scientific research in this field.
